Skip to main content
. Author manuscript; available in PMC: 2020 Jul 24.
Published in final edited form as: Lancet Haematol. 2019 Oct 31;6(12):e638–e649. doi: 10.1016/S2352-3026(19)30166-8

Figure 3. Survival outcomes according to the IPSM score in patients with non-advanced and advanced systemic mastocytosis.

Figure 3

Kaplan–Meier curves show the probability of overall survival (A, C) and progression-free survival (B, D) in patients with non-advanced and advanced systemic mastocytosis, defined by the IPSM.

Upper panels (A, B) show that patients with non-advanced systemic mastocytosis at low risk (no risk factors [low]) and intermediate risk (one [int-1] or two [int-2] additional risk factors) differed significantly and had a favourable outcome compared with patients with advanced systemic mastocytosis (AdvSM). Lower panels (C, D) show that patients with advanced systemic mastocytosis and no additional risk factors (AdvSM-1) differed significantly from those with one (AdvSM-2), two to three (AdvSM-3), or four to five (AdvSM-4) risk factors. IPSM=international prognostic scoring system for mastocytosis.